Evaluation of the diagnostic performance of nine commercial RT-PCR kits for the detection of SARS-CoV-2 in Colombia
© 2021 Wiley Periodicals LLC..
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to the design and development of multiple reverse-transcription polymerase chain reaction kits aimed to facilitate the rapid scale-up of molecular testing for massive screening. We evaluated the diagnostic performance of nine commercial kits, which showed optimal performance and high discriminatory power. However, we observed differences in terms of sensitivity, specificity, and E gene Ct Values and discuss these results in light of the influence of SARS-CoV-2 genetic variability and its potential impact in current molecular diagnostic assays.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Journal of medical virology - 93(2021), 9 vom: 29. Sept., Seite 5618-5622 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hernández, Carolina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Commercial kits |
|---|
| Anmerkungen: |
Date Completed 02.08.2021 Date Revised 05.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.27051 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324668295 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324668295 | ||
| 003 | DE-627 | ||
| 005 | 20231225190816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.27051 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1082.xml |
| 035 | |a (DE-627)NLM324668295 | ||
| 035 | |a (NLM)33913558 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hernández, Carolina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the diagnostic performance of nine commercial RT-PCR kits for the detection of SARS-CoV-2 in Colombia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2021 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to the design and development of multiple reverse-transcription polymerase chain reaction kits aimed to facilitate the rapid scale-up of molecular testing for massive screening. We evaluated the diagnostic performance of nine commercial kits, which showed optimal performance and high discriminatory power. However, we observed differences in terms of sensitivity, specificity, and E gene Ct Values and discuss these results in light of the influence of SARS-CoV-2 genetic variability and its potential impact in current molecular diagnostic assays | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a RT-PCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a commercial kits | |
| 650 | 4 | |a molecular diagnosis | |
| 650 | 4 | |a performance | |
| 650 | 7 | |a Reagent Kits, Diagnostic |2 NLM | |
| 700 | 1 | |a Florez, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Castañeda, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Ballesteros, Nathalia |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Castillo, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Rico, Angelica |e verfasserin |4 aut | |
| 700 | 1 | |a Pardo, Liseth |e verfasserin |4 aut | |
| 700 | 1 | |a Paniz-Mondolfi, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez, Juan David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 93(2021), 9 vom: 29. Sept., Seite 5618-5622 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2021 |g number:9 |g day:29 |g month:09 |g pages:5618-5622 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.27051 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2021 |e 9 |b 29 |c 09 |h 5618-5622 | ||